{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:51:26Z","timestamp":1762325486364,"version":"build-2065373602"},"reference-count":65,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pet.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["PET Clinics"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.cpet.2022.11.006","type":"journal-article","created":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T07:44:43Z","timestamp":1672213483000},"page":"233-242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Paragangliomas and Pheochromocytomas"],"prefix":"10.1016","volume":"18","author":[{"given":"Charles","family":"Marcus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rathan M.","family":"Subramaniam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.cpet.2022.11.006_bib1","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMra1806651","article-title":"Pheochromocytoma and paraganglioma","volume":"381","author":"Neumann","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.cpet.2022.11.006_bib2","first-page":"802","article-title":"Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979","volume":"58","author":"Beard","year":"1983","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cpet.2022.11.006_bib3","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejim.2018.01.015","article-title":"Incidence of pheochromocytoma and sympathetic paraganglioma in The Netherlands: a nationwide study and systematic review","volume":"51","author":"Berends","year":"2018","journal-title":"Eur J Intern Med"},{"issue":"6","key":"10.1016\/j.cpet.2022.11.006_bib4","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/MPA.0b013e3181ebb4f0","article-title":"The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer","volume":"39","author":"Chen","year":"2010","journal-title":"Pancreas"},{"issue":"3","key":"10.1016\/j.cpet.2022.11.006_bib5","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S0002-9610(00)00296-8","article-title":"Adrenal pheochromocytoma remains a frequently overlooked diagnosis","volume":"179","author":"Lo","year":"2000","journal-title":"Am J Surg"},{"issue":"6","key":"10.1016\/j.cpet.2022.11.006_bib6","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1445-5994.2000.tb04358.x","article-title":"Phaeochromocytomas discovered during coronial autopsies in Sydney, Melbourne and auckland","volume":"30","author":"McNeil","year":"2000","journal-title":"Aust N Z J Med"},{"issue":"9486","key":"10.1016\/j.cpet.2022.11.006_bib7","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(05)67139-5","volume":"366","author":"Lenders","year":"2005","journal-title":"Phaeochromocytoma Lancet"},{"issue":"5","key":"10.1016\/j.cpet.2022.11.006_bib8","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1210\/jc.2018-01707","article-title":"Pheochromocytoma characteristics and behavior differ depending on method of discovery","volume":"104","author":"Gruber","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.cpet.2022.11.006_bib9","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1245\/s10434-020-08220-3","article-title":"Update on pheochromocytoma and paraganglioma from the sso endocrine\/head and neck disease-site work group. part 1 of 2: advances in pathogenesis and diagnosis of pheochromocytoma and paraganglioma","volume":"27","author":"Patel","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.cpet.2022.11.006_bib10","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/MED.0000000000000724","article-title":"Supportive management of patients with pheochromocytoma\/paraganglioma undergoing noninvasive treatment","volume":"29","author":"Talvacchio","year":"2022","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"2","key":"10.1016\/j.cpet.2022.11.006_bib11","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1210\/endrev\/bnab019","article-title":"Personalized management of pheochromocytoma and paraganglioma","volume":"43","author":"Nolting","year":"2022","journal-title":"Endocr Rev"},{"issue":"2","key":"10.1016\/j.cpet.2022.11.006_bib12","first-page":"122","article-title":"Comparison of metaiodobenzylguanidine scintigraphy with positron emission tomography in the diagnostic work-up of pheochromocytoma and paraganglioma: a systematic review","volume":"57","author":"Rufini","year":"2013","journal-title":"Q\u00a0J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1016\/j.cpet.2022.11.006_bib13","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/RLU.0000000000000289","article-title":"Integrated whole-body PET\/MRI with 18F-FDG, 18F-FDOPA, and 18F-FDA in paragangliomas in comparison with PET\/CT: NIH first clinical experience with a single-injection, dual-modality imaging protocol","volume":"39","author":"Blanchet","year":"2014","journal-title":"Clin Nucl Med"},{"issue":"6","key":"10.1016\/j.cpet.2022.11.006_bib14","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2967\/jnumed.118.216796","article-title":"Metabolic subtyping of pheochromocytoma and paraganglioma by (18)f-fdg pharmacokinetics using dynamic PET\/CT scanning","volume":"60","author":"van Berkel","year":"2019","journal-title":"J\u00a0Nucl Med"},{"issue":"9","key":"10.1016\/j.cpet.2022.11.006_bib15","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.3390\/cancers12092424","article-title":"Usefulness of FDG-PET\/CT-Based Radiomics for the characterization and genetic orientation of pheochromocytomas before surgery","volume":"12","author":"Ansquer","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.cpet.2022.11.006_bib16","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2967\/jnumed.114.137034","article-title":"Correlation between in\u00a0vivo 18F-FDG PET and immunohistochemical markers of glucose uptake and metabolism in pheochromocytoma and paraganglioma","volume":"55","author":"van Berkel","year":"2014","journal-title":"J\u00a0Nucl Med"},{"issue":"9","key":"10.1016\/j.cpet.2022.11.006_bib17","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/jnci\/djs188","article-title":"Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography","volume":"104","author":"Timmers","year":"2012","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"16","key":"10.1016\/j.cpet.2022.11.006_bib18","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1200\/JCO.2006.09.6297","article-title":"Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma","volume":"25","author":"Timmers","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.cpet.2022.11.006_bib19","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/1754-9485.12620","article-title":"Genetic status determines (18) F-FDG uptake in pheochromocytoma\/paraganglioma","volume":"61","author":"Tiwari","year":"2017","journal-title":"J\u00a0Med Imaging Radiat Oncol"},{"issue":"12","key":"10.1016\/j.cpet.2022.11.006_bib20","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1177\/0284185118764206","article-title":"68)Ga-somatostatin receptor analogs and (18)F-FDG PET\/CT in the localization of metastatic pheochromocytomas and paragangliomas with germline mutations: a meta-analysis","volume":"59","author":"Kan","year":"2018","journal-title":"Acta Radiol"},{"issue":"4","key":"10.1016\/j.cpet.2022.11.006_bib21","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/RLU.0000000000004077","article-title":"Integrated PET\/MRI with 68Ga-DOTATATE and 18F-FDG in pheochromocytomas and paragangliomas: an initial study","volume":"47","author":"Xu","year":"2022","journal-title":"Clin Nucl Med"},{"issue":"2","key":"10.1016\/j.cpet.2022.11.006_bib22","doi-asserted-by":"crossref","first-page":"342","DOI":"10.2214\/AJR.21.26071","article-title":"Sporadic primary pheochromocytoma: a prospective intraindividual comparison of six imaging tests (CT, MRI, and PET\/CT Using (68)Ga-DOTATATE, FDG, (18)F-FDOPA, and (18)F-FDA)","volume":"218","author":"Jha","year":"2022","journal-title":"AJR Am J Roentgenol"},{"issue":"4","key":"10.1016\/j.cpet.2022.11.006_bib23","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1210\/clinem\/dgz314","article-title":"Pheochromocytoma and paraganglioma patients with poor survival often show brown adipose tissue activation","volume":"105","author":"Abdul Sater","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.cpet.2022.11.006_bib24","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/jch.13228","article-title":"Detection of brown adipose tissue by (18) F-FDG PET\/CT in pheochromocytoma\/paraganglioma: a systematic review","volume":"20","author":"Santhanam","year":"2018","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"issue":"10","key":"10.1016\/j.cpet.2022.11.006_bib25","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1007\/s00259-011-1872-3","article-title":"Clinical significance of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography for the assessment of 131I-metaiodobenzylguanidine therapy in malignant phaeochromocytoma","volume":"38","author":"Nakazawa","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.cpet.2022.11.006_bib26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40644-016-0084-2","article-title":"68)Ga-DOTATATE and (18)F-FDG PET\/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity","volume":"16","author":"Chang","year":"2016","journal-title":"Cancer Imaging"},{"issue":"7","key":"10.1016\/j.cpet.2022.11.006_bib27","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1007\/s00259-015-3268-2","article-title":"Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET\/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases","volume":"43","author":"Archier","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.cpet.2022.11.006_bib28","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1515\/jpem-2020-0354","article-title":"The utility of (68)Ga-DOTATATE PET\/CT in localizing primary\/metastatic pheochromocytoma and paraganglioma in children and adolescents - a single-center experience","volume":"34","author":"Jaiswal","year":"2021","journal-title":"J\u00a0Pediatr Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.cpet.2022.11.006_bib29","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/MNM.0000000000001130","article-title":"The impact of Ga-68 DOTATATE PET\/CT imaging on management of patients with paragangliomas","volume":"41","author":"Skoura","year":"2020","journal-title":"Nucl Med Commun"},{"issue":"3","key":"10.1016\/j.cpet.2022.11.006_bib30","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2967\/jnumed.118.211706","article-title":"Performance of (68)Ga-DOTA-Conjugated somatostatin receptor-targeting peptide PET in detection of pheochromocytoma and paraganglioma: a systematic review and Metaanalysis","volume":"60","author":"Han","year":"2019","journal-title":"J\u00a0Nucl Med"},{"issue":"5","key":"10.1016\/j.cpet.2022.11.006_bib31","doi-asserted-by":"crossref","first-page":"e0156044","DOI":"10.1371\/journal.pone.0156044","article-title":"Overexpression of L-type Amino acid transporter 1 (LAT1) and 2 (LAT2): novel markers of neuroendocrine tumors","volume":"11","author":"Barollo","year":"2016","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.cpet.2022.11.006_bib32","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1007\/s00259-017-3728-y","article-title":"Guideline for PET\/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA","volume":"44","author":"Bozkurt","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1016\/j.cpet.2022.11.006_bib33","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1007\/s00259-016-3586-z","article-title":"18)F-fluorodihydroxyphenylalanine PET\/CT in pheochromocytoma and paraganglioma: relation to genotype and amino acid transport system L","volume":"44","author":"Feral","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"10.1016\/j.cpet.2022.11.006_bib34","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1007\/s00259-012-2087-y","article-title":"Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis","volume":"39","author":"Treglia","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.cpet.2022.11.006_bib35","doi-asserted-by":"crossref","DOI":"10.1097\/RLU.0b013e31829aface","article-title":"18F-DOPA PET\/CT in the evaluation of hereditary SDH-deficiency paraganglioma-pheochromocytoma syndromes","volume":"39","author":"Marzola","year":"2014","journal-title":"Clin Nucl Med"},{"issue":"9","key":"10.1016\/j.cpet.2022.11.006_bib36","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1210\/jc.2011-0333","article-title":"Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy","volume":"96","author":"King","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.cpet.2022.11.006_bib37","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.1210\/jc.2009-1248","article-title":"Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma","volume":"94","author":"Timmers","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.cpet.2022.11.006_bib38","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.nucmedbio.2019.04.003","article-title":"68)Ga-DOTATOC PET\/CT in the localization of head and neck paraganglioma compared with (18)F-DOPA PET\/CT and (123)I-MIBG SPECT\/CT","volume":"71","author":"Kroiss","year":"2019","journal-title":"Nucl Med Biol"},{"issue":"6","key":"10.1016\/j.cpet.2022.11.006_bib39","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1002\/hed.25604","article-title":"Tumor multifocality with vagus nerve involvement as a phenotypic marker of SDHD mutation in patients with head and neck paragangliomas: a (18) F-FDOPA PET\/CT study","volume":"41","author":"Amodru","year":"2019","journal-title":"Head Neck"},{"issue":"4","key":"10.1016\/j.cpet.2022.11.006_bib40","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1210\/jc.2017-02324","article-title":"18F-FDOPA PET\/CT imaging of MAX-related pheochromocytoma","volume":"103","author":"Taieb","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.cpet.2022.11.006_bib41","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s00259-017-3833-y","article-title":"Quantitative (18)F-DOPA PET\/CT in pheochromocytoma: the relationship between tumor secretion and its biochemical phenotype","volume":"45","author":"Amodru","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1016\/j.cpet.2022.11.006_bib42","doi-asserted-by":"crossref","first-page":"T135","DOI":"10.1530\/ERC-15-0175","article-title":"15 YEARS OF paraganglioma: imaging and imaging-based treatment of pheochromocytoma and paraganglioma","volume":"22","author":"Castinetti","year":"2015","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"10.1016\/j.cpet.2022.11.006_bib43","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1530\/EJE-06-0712","article-title":"The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome","volume":"156","author":"Kaji","year":"2007","journal-title":"Eur J Endocrinol"},{"issue":"17","key":"10.1016\/j.cpet.2022.11.006_bib44","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1158\/1078-0432.CCR-14-2751","article-title":"Superiority of [68Ga]-DOTATATE PET\/CT to other functional imaging modalities in the localization of SDHB-associated metastatic pheochromocytoma and paraganglioma","volume":"21","author":"Janssen","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.cpet.2022.11.006_bib45","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1677\/ERC-07-0217","article-title":"Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations","volume":"15","author":"Zelinka","year":"2008","journal-title":"Endocr Relat Cancer"},{"issue":"10","key":"10.1016\/j.cpet.2022.11.006_bib46","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1007\/s00259-016-3357-x","article-title":"PET\/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT\/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma","volume":"43","author":"Janssen","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.cpet.2022.11.006_bib47","doi-asserted-by":"crossref","first-page":"186","DOI":"10.2967\/jnumed.115.161018","article-title":"68Ga-DOTATATE PET\/CT in the localization of head and neck paragangliomas compared with other functional imaging modalities and CT\/MRI","volume":"57","author":"Janssen","year":"2016","journal-title":"J\u00a0Nucl Med"},{"issue":"10","key":"10.1016\/j.cpet.2022.11.006_bib48","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1007\/s12094-021-02622-9","article-title":"Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas","volume":"23","author":"Garcia-Carbonero","year":"2021","journal-title":"Clin Transl Oncol"},{"issue":"6","key":"10.1016\/j.cpet.2022.11.006_bib49","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.cpet.2022.11.006_bib50","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/cen.12542","article-title":"Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis","volume":"81","author":"Niemeijer","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"10.1016\/j.cpet.2022.11.006_bib51","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1002\/ijc.28913","article-title":"SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma","volume":"135","author":"Hadoux","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cpet.2022.11.006_bib52","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3389\/fendo.2020.00061","article-title":"Temozolomide is a potential therapeutic tool for patients with metastatic pheochromocytoma\/paraganglioma-case report and review of the literature","volume":"11","author":"Tong","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"10.1016\/j.cpet.2022.11.006_bib53","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1530\/ERC-21-0392","article-title":"SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma","volume":"29","author":"Perez","year":"2022","journal-title":"Endocr Relat Cancer"},{"issue":"12","key":"10.1016\/j.cpet.2022.11.006_bib54","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s41416-019-0474-x","article-title":"A\u00a0phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial","volume":"120","author":"O'Kane","year":"2019","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.cpet.2022.11.006_bib55","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s12020-017-1359-5","article-title":"Phase II trial of pazopanib in advanced\/progressive malignant pheochromocytoma and paraganglioma","volume":"57","author":"Jasim","year":"2017","journal-title":"Endocrine"},{"issue":"7","key":"10.1016\/j.cpet.2022.11.006_bib56","doi-asserted-by":"crossref","first-page":"R239","DOI":"10.1530\/ERC-20-0043","article-title":"Antiangiogenic therapies for pheochromocytoma and paraganglioma","volume":"27","author":"Jimenez","year":"2020","journal-title":"Endocr Relat Cancer"},{"issue":"8","key":"10.1016\/j.cpet.2022.11.006_bib57","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.3390\/cancers12082307","article-title":"Phase II clinical trial of pembrolizumab in patients with progressive metastatic pheochromocytomas and paragangliomas","volume":"12","author":"Jimenez","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.cpet.2022.11.006_bib58","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2967\/jnumed.118.217463","article-title":"Efficacy and safety of high-specific-activity (131)I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma","volume":"60","author":"Pryma","year":"2019","journal-title":"J\u00a0Nucl Med"},{"issue":"5","key":"10.1016\/j.cpet.2022.11.006_bib59","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00259-008-0715-3","article-title":"EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy","volume":"35","author":"Giammarile","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"10.1016\/j.cpet.2022.11.006_bib60","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.2967\/jnumed.120.259697","article-title":"Systemic Radiopharmaceutical therapy of pheochromocytoma and paraganglioma","volume":"62","author":"Carrasquillo","year":"2021","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2022.11.006_bib61","doi-asserted-by":"crossref","first-page":"778322","DOI":"10.3389\/fendo.2022.778322","article-title":"[(177)Lu]Lu-DOTA-TATE and [(131)I]MIBG phenotypic imaging-based therapy in metastatic\/inoperable pheochromocytomas and paragangliomas: comparative results in a single center","volume":"13","author":"Prado-Wohlwend","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"10.1016\/j.cpet.2022.11.006_bib62","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/cen.14106","article-title":"Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: a systematic review and meta-analysis","volume":"91","author":"Satapathy","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"10.1016\/j.cpet.2022.11.006_bib63","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s00259-021-05632-5","article-title":"Efficacy and safety of (225)Ac-DOTATATE targeted alpha therapy in metastatic paragangliomas: a pilot study","volume":"49","author":"Yadav","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.cpet.2022.11.006_bib64","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s13139-015-0331-7","article-title":"Diagnostic performance of (68)Ga-DOTATATE PET\/CT, (18)F-FDG PET\/CT and (131)I-MIBG scintigraphy in Mapping metastatic pheochromocytoma and paraganglioma","volume":"49","author":"Tan","year":"2015","journal-title":"Nucl Med Mol Imaging"},{"issue":"8","key":"10.1016\/j.cpet.2022.11.006_bib65","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1007\/s00259-012-2119-7","article-title":"A\u00a0comparison of the performance of (6)(8)Ga-DOTATATE PET\/CT and (1)(2)(3)I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma","volume":"39","author":"Maurice","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["PET Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859822000931?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859822000931?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:09:50Z","timestamp":1761563390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556859822000931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1556859822000931"],"URL":"https:\/\/doi.org\/10.1016\/j.cpet.2022.11.006","relation":{},"ISSN":["1556-8598"],"issn-type":[{"type":"print","value":"1556-8598"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Paragangliomas and Pheochromocytomas","name":"articletitle","label":"Article Title"},{"value":"PET Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpet.2022.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}